| Drug Name | Nivolumab |
|---|---|
| Other Drug Names | BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo |
| Chemical Name |
immunoglobulin G4-kappa, anti-[Homo sapiens PDCD1
(programmed cell death 1, PD-1, PD1, CD279)], Homo sapiens
monoclonal antibody; gamma1 heavy chain (1-440) [Homo sapiens VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (114-440)], (127-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) - IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (219-219'':222- 222'')-bisdisulfide dimer |
| Formula | C6362H9862N1712O1995S42 |
| Mol. Wt. | 143.6 kDa |
| CAS No. | 946414-94-4 |
| UNII | 31YO63LBSN |
| Target-based Actions | Programmed cell death protein 1 inhibitor |
| ATC Codes | L01XC17 |
| Highest Status | 2015年批准上市 |
| Originator Company | Bristol-Myers Squibb |
| Structure |
 |